PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial

Journal of Urology

Volumn 184, Issue 5, 2010, Pages 1947-1952

  Aubin, Sheila M J ^a   Reid, Jennifer ^a   Sarno, Mark J ^a   Blase, Amy ^a   Aussie, Jacqueline ^a   Rittenhouse, Harry ^a   Rittmaster, Roger ^b   Andriole, Gerald L ^c   Groskopf, Jack ^a  

^a Gen Probe Incorporated   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

Logistic models; Prostate cancer antigen 3, human; Prostate specific antigen; Prostatic neoplasms; ROC curve

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; AZASTEROID; ENZYME INHIBITOR; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL INDICATOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FAMILY HISTORY; GLEASON SCORE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER GENE 3; RISK REDUCTION; SCORING SYSTEM; TUMOR GENE; URINALYSIS; VALIDATION STUDY; BIOPSY; CONTROLLED CLINICAL TRIAL (TOPIC); PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; URINE;

ANTIGENS, NEOPLASM; AZASTEROIDS; BIOPSY; CONTROLLED CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; MALE; PLACEBOS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77957845752     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.06.098     Document Type: Article

References (12)

1. M.J.G. Bussemakers, A. Van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly over-expressed in prostate cancer Cancer Res 59 1999 5975
2. J.B. De Kok, G.W. Verhaegh, and R.W. Roelofs DD3PCA3, a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695
3. D. Hessels, M.T. Klein Gunnewiek, and I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8
4. L.J. Sokoll, W. Ellis, and P. Lange A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy Clin Chim Acta 389 2008 1
5. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
6. J. Groskopf, S.M. Aubin, and I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089
7. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532
8. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804
9. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975
10. G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial J Urol 172 2004 1314
11. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver-operating characteristic curves: a nonparametric approach Biometrics 44 1988 837
12. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081